[HTML][HTML] Vaccine for prevention of mild and moderate-to-severe influenza in children
VK Jain, L Rivera, K Zaman, RA Espos Jr… - … England Journal of …, 2013 - Mass Medical Soc
Background Commonly used trivalent vaccines contain one influenza B virus lineage and
may be ineffective against viruses of the other B lineage. We evaluated the efficacy of a …
may be ineffective against viruses of the other B lineage. We evaluated the efficacy of a …
Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16 year olds: a randomized, controlled, phase II trial in Latin America
LÁ Villar, DM Rivera-Medina… - The Pediatric …, 2013 - journals.lww.com
Background: The dengue virus is a member of the Flavivirus (FV) genus, which also includes
the yellow fever virus. Dengue disease is caused by any 1 of 4 dengue virus serotypes and …
the yellow fever virus. Dengue disease is caused by any 1 of 4 dengue virus serotypes and …
Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose …
…, H Janosczyk, MC Keefer, DM Rivera M… - medRxiv, 2021 - medrxiv.org
Background This study evaluated the safety and immunogenicity of an AS03-adjuvanted
SARS-CoV-2 recombinant protein candidate vaccine, CoV2 preS dTM. Methods This Phase 2, …
SARS-CoV-2 recombinant protein candidate vaccine, CoV2 preS dTM. Methods This Phase 2, …
Prospective surveillance of Zika virus at the end of the Americas' outbreak: An unexpected outcome
…, J Ojeda, EJ Garcia-Rivera, DM Rivera… - Frontiers in Tropical …, 2022 - frontiersin.org
Objective The French Polynesia Zika virus (ZIKV) outbreak (2013–2014) broadened the
known manifestations of ZIKV disease (ZVD) to include neural and congenital syndromes. A …
known manifestations of ZIKV disease (ZVD) to include neural and congenital syndromes. A …
Unique immune blood markers between severe dengue and sepsis in children
DM Salgado, GM Rivera, WA Pinto… - The Pediatric …, 2023 - journals.lww.com
Background: Pediatric dengue and sepsis share clinical and pathophysiologic aspects.
Multiple inflammatory and regulatory cytokines, decoy receptors and vascular permeability …
Multiple inflammatory and regulatory cytokines, decoy receptors and vascular permeability …
Disease activity in mitral annular calcification: a multimodality study
…, WSA Jenkins, AT Vesey, MK Doris… - Circulation …, 2019 - Am Heart Assoc
Background: Mitral annular calcification (MAC) is associated with cardiovascular events and
mitral valve dysfunction. However, the underlying pathophysiology remains incompletely …
mitral valve dysfunction. However, the underlying pathophysiology remains incompletely …
Computed tomography aortic valve calcium scoring for the assessment of aortic stenosis progression
MK Doris, W Jenkins, P Robson, T Pawade… - Heart, 2020 - heart.bmj.com
Objective CT quantification of aortic valve calcification (CT-AVC) is useful in the assessment
of aortic stenosis severity. Our objective was to assess its ability to track aortic stenosis …
of aortic stenosis severity. Our objective was to assess its ability to track aortic stenosis …
Sex-specific computed tomography coronary plaque characterization and risk of myocardial infarction
MC Williams, J Kwiecinski, M Doris, P McElhinney… - Cardiovascular …, 2021 - jacc.org
Objectives This study was designed to investigate whether coronary computed tomography
angiography assessments of coronary plaque might explain differences in the prognosis of …
angiography assessments of coronary plaque might explain differences in the prognosis of …
Efficacy of a tetravalent dengue vaccine in children in Latin America
…, JL Arredondo-García, DM Rivera… - … England Journal of …, 2015 - Mass Medical Soc
Background In light of the increasing rate of dengue infections throughout the world despite
vector-control measures, several dengue vaccine candidates are in development. Methods …
vector-control measures, several dengue vaccine candidates are in development. Methods …
[HTML][HTML] Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis
…, DM Rivera-Medina, L Rivera… - … England Journal of …, 2006 - Mass Medical Soc
Background The safety and efficacy of an attenuated G1P[8] human rotavirus (HRV) vaccine
were tested in a randomized, double-blind, phase 3 trial. Methods We studied 63,225 …
were tested in a randomized, double-blind, phase 3 trial. Methods We studied 63,225 …